bluuebunny/crossref_metadata_2025_split huggingface dataset:
The effect of hapten on the clinical efficacy and survival of patients with liver cancer treated by UMIPIC.
Authors: Gao Feng , Jing Peng , Liu Jian , Han Wei , Xu Xingyou , Shang Wei , Feng Jianbin , Zhang Peicheng , Zhang Xiaomin , He Guangyong , Wu Yanfei , Yu Baofa 
Published: May 2020

e16130 Background: To observe the effect of adjuvant on the clinical efficacy and survival period of patients with liver cancer treated by UMIPIC (Ultra-minimum Incision personalized intratumoral chemoimmunotherapy). Methods: 156 liver cancer patients who were treated with UMIPIC with hapten or without hapten from January 2011 to December 2015 were selected for the study objects, including 124 cases with hapten as studying group and 32 cases without hapten as comparing group. All patients signed the treatment consent, treated according to the treatment guidelines of UMIPIC, followed up for the efficacy and the survival period of all patients more than 3 months, and observed whether there was effect on the clinical efficacy, adverse reactions, survival period and survival rate of patients with liver cancer patients treated with UMIPIC. Results: The common side effects of hapten group were fever 45.16%, pain 27.42%, hemoglobin reduction 14.78%, leucopenia 11.97%, thrombocytopenia 10.26%, liver function damage 5.26%, nausea 4.03%, renal dysfunction 2.61%. No rash, neurotoxicity and hair loss were found; The common adverse reactions in the non hapten group were fever 40.63%, pain 25.00%, hemoglobin reduction 17.24%, leucopenia 13.79%, thrombocytopenia 10.34%, nausea 6.25%. No other adverse reactions were found; there was no difference between the two groups (P > 0.05). The benefit rate of hapten group was 89.06% lower than that of non hapten group (94.74%) (P > 0.05). According to the follow-up results, the mean and median survival time of hapten group was 26.421 and 9.930 months, significantly higher than that of non hapten (16.473 and 7.230 months) (P < 0.05).The 1-year, 2-year, 3-year and 5-year survival rates of adjuvant group respectively were 45.69%, 33.33%, 25.68% and 20.83%,The 1-year, 2-year, 3-year and 5-year survival rates in the adjuvant free group respectively were 27.50%, 20.59%, 14.81% and 14.29%, The 1-year survival rate of hapten group was significantly higher than that of non hapten group (P < 0.05). Conclusions: There is no significant difference in the adverse reactions and clinical efficacy of UMIPIC in the treatment of liver cancer patients with and without hapten. Adding hapten can significantly prolong the survival time and improve the survival rate of patients with liver cancer patients treated with UMIPIC.
Acceptance of preventive colonoscopy in rural areas in Germany.
Authors: Fahlke Joerg , Friedrichs Kai-Stephan , Fahlke Sophie , Habermann Peter , Barroso da Fonseca Lorenz , Lippert Hans , Ridwelski Karsten 
Published: May 2020

e16143 Background: Colorectal cancer is one of the most common types of cancer in Germany. Colonoscopy is certainly one of the most efficient diagnostic methods in preventing and early detection of colorectal cancer. Nevertheless, acceptance of colonoscopy as a useful screening method among the population in Germany is moderate, with around 22% of those entitled to claim. Methods: In order to better assess the reasons for the low level of acceptance, patients who presented themselves from March 2016 to June 2017 in the General Surgery Clinic of the Johanniter Hospital Stendal were randomly selected and interviewed using a questionnaire. These randomized patients did not suffer from colorectal cancer. The questionnaire asked whether the patients had participated in Colon Cancer Screening and if not for what reasons. Respondents were asked to choose among 8 preselected reasons or give their own. The options for not having participated in colorectal cancer screening were: lack of knowledge about the offer of colorectal cancer screening, fear of the examination, fear of cancer as an outcome, lack of time for the examination, didn't get an appointment for the exam, place of examination is too far away, excessive travel costs, examination makes no sense, and other (free text entry). Results: A total of 238 questionnaires were completed, 235 of which could be evaluated with regard to gender and age. The proportion between women and men was balanced (m 123, w 112). Surprisingly, contrary to expectations, significantly more respondents participated in colorectal cancer screening than not. There were no differences between females and males. The participation rate in colorectal cancer screening was 71%, which was significantly higher than expected. A significantly lower rate was found in respondents ages between 55 to 60 years old, with 41% of men and 67% of women having participated in a colorectal screening. Asked specifically about the reasons why they did not take advantage of the preventive medical check-up, the men of the affected age group (55-60 years) gave: fear of the examination, fear of cancer as an outcome, and examination makes no sense. Conclusions: The results underline the importance of determining why the acceptance of colorectal cancer screening has not yet reached the desired level. Considering and discussing these three main reasons show that there are opportunities to continuously increase awareness of the importance of participation rates in colonoscopy as a screening method for colorectal cancer through target public education.
Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers.
Authors: Peng Jenny , Batra Atul , Cheung Winson Y. 
Published: May 2020

e16504 Background: Advanced gastroesophageal cancers (AGCs) are aggressive tumors. Prior research has demonstrated that patients with poor prognostic cancers are inconsistently or infrequently referred to oncology specialists because of misperceptions that oncologic treatments are futile and do not alter overall outcomes. The aim of this real-world study was to characterize the attrition of patients with AGCs as they proceed through the diagnostic-therapeutic pathway and to assess its impact on survival. Methods: A retrospective population-based analysis was performed using data from the cancer registry and electronic medical records in a large province (Alberta, Canada). Patients diagnosed with AGCs from 2010 to 2017 were included. Details on demographics, setting of referral (outpatient or inpatient), time from referral to consultation to treatment, and modality of treatment (best supportive care, systemic therapy, and/or radiation) were collected. Logistic regression was used to determine factors associated with referral. Cox regression models were constructed to determine factors associated with overall survival (OS). Results: We identified 1,244 patients, of whom 633 (51%) had gastric and 611 (49%) had esophageal cancer. Median age was 67 years (IQR 58-78 years) and 72% were men. In this cohort, 87% were referred to a cancer center, 80% were seen by an oncologist, and only 44% received first-line treatment. Median time from referral to consultation was 13 days and consultation to treatment was 12 days. In logistic regression, advanced age (OR 0.274; 95% CI 0.183-0.412, p<0.0001) and those with a gastric primary (OR 0.437; 95% CI 0.303-0.628, p<0.0001) were less likely to be referred. In Cox regression, receipt of chemotherapy (HR 0.79; 95% CI 0.76-0.83, p<0.0001) and shorter time from consultation to treatment (HR 0.994; 95% CI 0.991-0.997, p<0.0001) were predictive of better OS. The setting of referral (inpatient vs. outpatient) was not significantly associated with OS (HR 1.11; 95% CI 0.85-1.45, p=0.414). Conclusions: Attrition was most significant as patients proceeded from consultation to treatment. Streamlining processes to narrow the consultation to treatment window may increase the number of patients with AGCs who may be eligible for potentially effective therapies or new clinical trials, which can improve their overall outcomes.
Cancer genomics-based screening of new therapeutic targets and biomarkers for esophageal cancer.
Authors: Daigo Yataro , Takano Atsushi , Nakamura Yusuke 
Published: May 2020

e16514 Background: Since the number of esophageal cancer patients who show objective response to standard therapies is still small, development of new anti-cancer agents with minimum risk of adverse events and highly precise molecular biomarkers is eagerly awaited. Methods: We have been screening novel therapeutic targets and their companion diagnostics for esophageal cancers as follows; i) To identify up-regulated genes in esophageal cancers by the gene expression profile analysis, ii) To verify the candidate genes for their low expression in normal tissues, iii) To validate the clinicopathological significance of their protein expression by tissue microarray covering 265 esophageal cancers, and iv) To verify their function for the growth of the esophageal cancer cells by siRNAs and gene transfection assays. Results: We identified dozens of candidate oncoproteins and selected a metyltransferase ESOC1 (esophageal cancer-associated oncoprotein 1). Immunohistochemical analysis revealed that ESOC1 positivity was observed in 68.5% of esophageal cancers and associated with tumor size. Moreover ESOC1 expression was an independent prognostic factor for esophageal cancer patients. Suppression of ESOC1 expression by its siRNAs inhibited growth of esophageal cancer cell lines. Introduction of ESOC1 increased the growth activity of mammalian cells, suggesting that ESOC1 is likely to be a prognostic biomarker and therapeutic target for esophageal cancers. Conclusions: Cancer genomics-based approach could be useful for the development of new cancer biomarkers as well as therapeutic targets for small molecules, antibodies, nucleic acid drugs, and immunotherapies.
Is the peritoneal lavage cytology coincided with peritoneal metastasis for gastric cancer?
Authors: Wang Wei , Xiong Wenjun , Peng Yaohui , Li Jin , Huang Haipeng , Zheng Yansheng , Luo Lijie , Wan Jin 
Published: May 2020

e16533 Background: Gastric cancer (GC) with peritoneal metastasis (PM) is associated with a poor prognosis. The free cancer cells are the prerequisite of peritoneal metastasis. Peritoneal lavage cytology (PLC) is the main measure to identify the free cancer cells, but its positive rate is relatively low. This study aims to investigate the association between the result PLC and peritoneal metastasis for GC. Methods: From November 2017 to December 2019, 33 patients with GC were confirmed with PM through computerized tomography or diagnostic laparoscopy. The inflow and outflow catheters were inserted laparoscopically in all patients for postoperative hyperthermic intraperitoneal chemotherapy. PLC was performed with at least 200 ml of fluid and examined by measures of cytology and immunocytopathology. Ascites was aspirated if detected or 500 milliliter of normal saline infused the Douglas cavity, para-colic gutters and the right and left sub-phrenic cavity and then aspirated. Results: There were 15 males and 18 females and the median age was 56 (24-84) years old. All patients had a cT4a/cT4b and an N-positive tumor. The overall positive PLC (PLC+) rate was 63.6% (21/33). The distribution of Lauren classification was respectively 5 (15.2%) intestinal, 26 (78.8%) diffused and 2 (6.1%) mixed tumor. The diffused cases had a higher rate of PLC+ ( P = 0.004). All 5 intestinal GC had a negative PLC (PLC-). 71.4% (20/28) of patients with a grade G3/G4 had a PLC+, compared, no PLC+ was recorded in 5 grade G1/G2 patients (P = 0.003). The median peritoneal carcinomatosis index (PCI) was 14 (1-39). The PLC+ rate was 94.7% (18/19) in PCI > = 10 group and 21.4% (3/14) in PCI < 10 group ( P < 0.001). The median ascites was 200 (0-7000) ml. The PLC+ rate was 88.2% 15/17) in ascites > = 200 ml group and 37.5% (6/16) in ascites < 10 ml ( P = 0.002). The median follow-up was 13(1-27) months and the overall survival was 75.8%, but no significance was detected between PLC+ group and PLC- group. Conclusions: The present study suggested that the result of PLC was not completely coincided with PM for GC by measures of cytology and immunocytopathology, especially for intestinal and grade G1/G2 tumor.
Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel) versus EOX/EOF (epirubicin, oxaliplatin and capecitabine or fluorouracil) for locally advanced, resectable gastric or gastro-oesophageal junction (GOJ) adenocarcinoma: A regional center experience.
Authors: Wong Emily , Tan Alvin Boon Tee 
Published: May 2020

e16556 Background: The FLOT4-AIO trial demonstrated a survival benefit in patients with resectable gastric or GOJ adenocarcinoma who received FLOT compared to ECX/ECF (epirubicin, cisplatin, capecitabine or fluorouracil) chemotherapy, but there has been no direct comparison made between FLOT and EOX/EOF regimens in randomised trials to date. Methods: Patients with locally advanced, resectable gastric or GOJ adenocarcinoma treated between December 2012 to December 2019 with FLOT or EOX/EOF in the Midland region were identified. FLOT patients received four preoperative and four postoperative 2-week cycles of 50 mg/m2 docetaxel, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin and 2600 mg/m2 fluorouracil as 24-h infusion on day 1. The EOX/EOF patients received three preoperative and three postoperative 3-week cycles of 50 mg/m2 epirubicin, 130 mg/m2 oxaliplatin on day 1 plus either 200 mg/m2 fluorouracil as continuous intravenous infusion or 1250 mg/m2 capecitabine orally on days 1 to 21. We compared the pathological response and tolerability of these regimens. Results: 38 patients received FLOT and 36 patients received EOX/EOF chemotherapy. The median age was 60 and 63.5 respectively. R0 resection was achieved in 31 out of 35 FLOT patients (89%), and 32 out of 35 EOX/EOF patients (91%) who proceeded with surgical resection following pre-operative chemotherapy. AJCC tumour regression score 0-1 was seen in 14 (37%) FLOT patients and 12 (33%) EOX/EOF patients. 30 (79%) FLOT patients and 29 (80%) EOX/EOF patients completed their planned preoperative courses. In the postoperative phase, 20 (56%) FLOT patients and 9 (25%) EOX/EOF patients completed their planned course. Dose reductions occurred in 27% of FLOT patients and 15% of EOX/EOF patients. Grade 3/4 adverse events occurred in 30% of FLOT cycles, and 19% of EOX/EOF cycles administered. Conclusions: Perioperative FLOT and EOX/EOF chemotherapy had similar pathological response, with higher completion of postoperative chemotherapy with FLOT regime.
Cytokine status in the omentum and peritoneum in metastatic gastric cancer.
Authors: Zlatnik Elena Yu. , Kit Oleg I. , Sagakyants Aleksandr B. , Zolotareva Ekaterina I. , Shulgina Oksana G. , Novikova Inna A. , Samoylenko Nikolay S. , Soldatkina Natalya V. , Gevorkyan Yuriy A. , Dzhenkova Elena A. , Kharagezov Dmitry A. , Dashkov Andrey V. , Kolesnikov Vladimir E. , Poluektov Sergey I. , Kaymakchi Dmitry O. , Dontsov Vladimir A. , Shaposhnikov Alexander V. , Petrov Dmitry S. , Fomenko Yuriy A. 
Published: May 2020

e16557 Background: Gastric cancer (GC) is one of the most common malignant tumors and the second most common cause of cancer deaths in Russia. Many researchers note the ambiguous role of cytokines in the pathogenesis of tumor processes. The purpose of the study was to determine characteristics of the cytokine status in the omentum and peritoneum of patients with metastatic GC. Methods: The main group (Mgr) included 23 patients with T2-4N0-3M1 GC with metastases to the peritoneum and greater omentum, the mean age 58.9±9.7 years. The comparison group (Cgr) included 20 non-cancer patients, the mean age 55.9±9.7 years. Tissues of the omentum (OT) and peritoneum (PT) were obtained from all patients during cytoreductive and diagnostic surgeries. Ex tempore tissues were disintegrated using BD Medimachine (USA) with 0.9% NaCl; the cell suspension was centrifuged, and the supernatant was collected and aliquoted. Levels of cytokines IL-1β, IL-2, IL-6, IL-8, IL-18, TNF-α, IL-10 (Vektor-Best, Russia) and IL-1RA (eBioscience, Austria) were determined by ELISA. The results were expressed as the specific content per 1 g of protein evaluated by the biuret method (pg/mL/g of protein). Statisical analysis of the results was performed with the Statistica 10 program (StatSoft Inc., USA). Significance of differences was evaluated using the Mann-Whitney and Wilkinson tests; differences were considered significant at p < 0.05. Results: In Cgr, levels of IL-6, IL-8, IL-18 and IL-1β in OT were 4.1±1.1, 3.4±0.7, 21.2±5.5 and 10.8±2.1, while in Mgr – 55.3±24.4, 32.5±13.8, 144.9±48.4 and 21.01±5.4 pg/mL/g of protein, i.e. 13.7, 9.5, 6.9 and 1.9 times (p≤0.05) higher than in Cgr, respectively. The specific content of IL-1RA in OT was 12.6 times higher, p≤0.05 (215.7±69.8 vs. 2723.1±730.1), and the IL-10 concentration did not differ significantly. In PT of Cgr, levels of IL-8, IL-18 and IL-6 were 9.8±7.3, 35.2±21.7, 7.5±3.7, and in Mgr – 250.7±21.4, 322.9±16.9, 61.1±27.6 pg/mL/g, i.e. 25.7, 9.2 and 8.2 times (p≤0.05) higher than in Cgr. IL-1RA in PT of Mgr was 24.4 times higher than in Cgr, p≤0.05 (7656.2±3160.3 vs. 357.69±180.86). Conclusions: A certain microenvironment is formed in OT and PT affected by metastases, with specific features in the ratio and concentrations of various cytokines, which undoubtedly contribute to the formation of a secondary tumor.
Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1–positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.
Authors: Chung Hyun Cheol , Kang Yoon-Koo , Chen Zhendong , Bai Yuxian , Wan Ishak Wan Zamaniah , Shim Byoung Yong , Park Youngiee , Koo Dong-Hoe , LU Jin Wei , Xu Jianming , Bhagia Pooja , Kuang Shu , Shih Chie-Schin , Qin Shukui 
Published: May 2020

e16586 Background: Approximately 75% of GC cases occur in Asian persons. Pembrolizumab has shown antitumor activity in global studies of GC. KEYNOTE-063 (NCT03019588) is a randomized, open-label, phase 3 trial in Asian patients with advanced PD-L1–positive (combined positive score [CPS] ≥1) GC that progressed after platinum + fluoropyrimidine chemotherapy. After the KEYNOTE-063 study began, results of the global KEYNOTE-061 study (NCT02370498) showed that pembrolizumab did not prolong overall survival (OS) vs paclitaxel in patients previously treated for advanced GC (median OS, 9.1 months vs 8.3 months; hazard ratio [HR], 0.82; 95% CI, 0.66-1.03; 1-sided P= 0.0421 [significance threshold for OS was 1-sided P= 0.0135]). Methods: Eligible patients were randomly assigned in a 1:1 ratio to receive pembrolizumab 200 mg Q3W for up to 35 cycles (~2 years) or standard-dose paclitaxel. The primary efficacy end points were OS and progression-free survival (PFS). Planned enrollment was ~360 patients. Results: Because pembrolizumab did not significantly prolong OS in KEYNOTE-061, enrollment in KEYNOTE-063 was discontinued after 94 patients were enrolled (47 patients in each treatment group). In these Asian patients, median OS was 8.4 months in the pembrolizumab group and 7.7 months in the paclitaxel group; median PFS was 1.9 months and 4.0 months, respectively (Table). Objective response rate (ORR) and median duration of response (DOR) are shown in the Table. Drug-related adverse events (AEs) occurred in 59.6% of patients receiving pembrolizumab and in 95.5% of patients receiving paclitaxel (Table). Conclusions: In this small sample of Asian patients with PD-L1–positive advanced GC, definitive conclusions are limited; however, second-line pembrolizumab monotherapy seems to be well tolerated in this patient population. Because this study was terminated early, there was insufficient power for comparisons between groups; therefore, these data should be viewed with caution. Clinical trial information: NCT03019588 . [Table: see text]
Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC).
Authors: Xu Li , Zhang Yaojun , Wang Xiaohui , Shi Mude , Wang Juncheng , Tang Yuhao , Fu Yizhen , Zhou Zhongguo , Chen Minshan 
Published: May 2020

e16593 Background: Our previous studies showed that TAI with modified FOLFOX increased tumor response and resection rate compared with conventional TACE in advanced HCC. PD-1/PD-L1 inhibitors have been demonstrated promising value in HCC. This study aims to evaluate the efficacy and safety of FOLFOX-TAI combined with Sintilimab (a PD-1 inhibitor) in locally advanced, potentially resectable HCC. Methods: This prospective, nonrandomized controlled phase II study is recruiting 40 pts with locally advanced, potentially resectable HCC (localized to semi-liver with invasion to branch of the portal vein). Pts in the combined group receive repeated 3-week cycles of Sintilimab 200mg IV Day1 and TAI with FOLFOX Day2 (Oxaliplatin 130 mg/m2, Leucovorin 400 mg/m2, 5-FU 400 mg/m2 and 5-FU 2400 mg/m2, next 46 hours). Pts in the control group only received TAI. Tumor assessment with RECIST 1.1 was performed every 2 cycles. The pts gained visible tumor shrinkage and opportunity for resection received surgical hepatectomy. Pts with stable disease (SD) or unconfirmed progression disease (PD) will receive repeated cycles until confirmed PD or intolerable toxicity, with max cycles of 8 for TAI and 16 for Sintilimab. The primary endpoint is progression or postoperative relapse free survival (PFS). Secondary endpoints include ORR, DCR, resection rate, OS, and safety. Results: As of Jan 10, 2020, 33 eligible pts were enrolled. All treatment related AEs were grade 1 or 2, including transaminase and bilirubin increase, nausea, hypoalbuminemia, rash, leucopenia, thrombopenia, and weight loss. No irAE and treatment related SAE was observed. Conclusions: TAI combined with Sintilimab attributed to high surgical conversion rate and good safety profile for locally advanced, potentially resectable HCC. Clinical trial information: NCT03869034 .
Does an association exist between liver fibrosis and non-HCC cancers.
Authors: Banskota Shristi Upadhyay , Farooq Muhammad Zain , Agrawal Rohit , Vohra Ishaan , Ba Aqeel Sheeba Habeeb , Lingamaneni Prasanth , Sherazi Syed Ali Amir , Moturi Krishna Rekha , Wang Yuchen 
Published: May 2020

e16594 Background: The association between liver fibrosis and hepatocellular cancer (HCC) is well established, however there is limitation of data on liver fibrosis and non-HCC cancers. The aim of this study was to explore the link between the degree of liver fibrosis and other cancers. Methods: We searched the electronic medical records of Stroger Hospital who underwent liver elastography from January 1st, 2014 to December 31st, 2018 and had cancer. We extracted variables: demographics, cancer histology and metastatic status and then stratified patient into categories based the fibrosis stage. Results: Our analysis identified 103 patients with non-advanced fibrosis (F0-F2) and 74 with advanced fibrosis (F3-F4). HCC was seen in 33.3% of the patients with advanced fibrosis while genitourinary (GU) was the second most common cancer. Adenocarcinoma comprised 21% of these cancers and around 46% were metastatic. Of the 104 patients with non-advanced fibrosis, HCC was seen in 3.77% while gastrointestinal (GI) and GU cancers were seen in 24.27% and 12.62% respectively. Adenocarcinoma was most common (40%) in this group as well (Table). Conclusions: Our study not only reiterates the fact that the degree of liver fibrosis is proportional to the presence of HCC, but it also reports the association of liver fibrosis with several non-HCC cancers. The meaning of these associations is unclear, but it provides an area of further research to explore if causality exists. [Table: see text]